BIOA
BioAge Labs, Inc.
Biotechnology
Market Cap$664M
5Y Perf.-11.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BIOA vs RVMD
Revenue, margins, valuation, and 5-year total return — side by side.
RVMD
Revolution Medicines, Inc.
Biotechnology
Market Cap$32.12B
5Y Perf.+233.1%
BIOA vs RVMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BIOA | RVMD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $664M | $32.12B |
| Revenue (TTM) | $9M | $0.00 |
| Net Income (TTM) | $-81M | $-1.37B |
| Gross Margin | 99.2% | — |
| Operating Margin | -10.3% | — |
| Total Debt | $6M | $159M |
| Cash & Equiv. | $189M | $384M |
BIOA vs RVMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BIOA
RVMD
| Stock | Sep 24 | May 26 | Return |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | 100 | 88.8 | -11.3% |
| Revolution Medicine… (RVMD) | 100 | 333.1 | +233.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BIOA vs RVMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BIOA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Revolution Medicines, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BIOA
BioAge Labs, Inc.
The Growth Play
BIOA carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 66.2%
- Lower volatility, beta 1.41, Low D/E 2.0%, current ratio 14.24x
- -13.3% revenue growth vs RVMD's -98.6%
Best for: growth exposure and sleep-well-at-night
RVMD
Revolution Medicines, Inc.
The Income Pick
RVMD is the clearest fit if your priority is income & stability and long-term compounding.
- beta 1.08
- 422.7% 10Y total return vs BIOA's 0.8%
- Beta 1.08, current ratio 7.14x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BIOA | -13.3% revenue growth vs RVMD's -98.6% |
| Quality / Margins | RVMD | 2.8% margin vs BIOA's -9.0% |
| Stability / Safety | RVMD | Beta 1.08 vs BIOA's 1.41 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | BIOA | +367.3% vs RVMD's +303.5% |
| Efficiency (ROA) | BIOA | -25.5% ROA vs RVMD's -59.1%, ROIC -210.2% vs -54.3% |
BIOA vs RVMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2022
BIOA vs RVMD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBIOALAGGINGRVMD
RVMDRevolution Medicines,…
2leads
BIOABioAge Labs, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs RVMDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BIOA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BIOA6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
RVMD5/6
Risk & VolatilityBeta, volatility, and downside exposure
RVMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BIOA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
BIOA and RVMD operate at a comparable scale, with $9M and $0 in trailing revenue.
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… |
|---|---|---|
| RevenueTrailing 12 months | $9M | $0 |
| EBITDAEarnings before interest/tax | -$93M | -$1.4B |
| Net IncomeAfter-tax profit | -$81M | -$1.4B |
| Free Cash FlowCash after capex | -$82M | -$1.1B |
| Gross MarginGross profit ÷ Revenue | +99.2% | — |
| Operating MarginEBIT ÷ Revenue | -10.3% | — |
| Net MarginNet income ÷ Revenue | -9.0% | — |
| FCF MarginFCF ÷ Revenue | -9.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +63.5% | -102.7% |
BIOA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — BIOA and RVMD each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… |
|---|---|---|
| Market CapShares × price | $664M | $32.1B |
| Enterprise ValueMkt cap + debt − cash | $481M | $31.9B |
| Trailing P/EPrice ÷ TTM EPS | -8.24x | -25.39x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 73.84x | — |
| Price / BookPrice ÷ Book value/share | 2.44x | 17.61x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — BIOA and RVMD each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
BIOA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
BIOA delivers a -27.9% return on equity — every $100 of shareholder capital generates $-28 in annual profit, vs $-83 for RVMD. BIOA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), BIOA scores 5/9 vs RVMD's 1/9, reflecting solid financial health.
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… |
|---|---|---|
| ROE (TTM)Return on equity | -27.9% | -83.2% |
| ROA (TTM)Return on assets | -25.5% | -59.1% |
| ROICReturn on invested capital | -2.1% | -54.3% |
| ROCEReturn on capital employed | -30.7% | -53.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 1 |
| Debt / EquityFinancial leverage | 0.02x | 0.10x |
| Net DebtTotal debt minus cash | -$183M | -$225M |
| Cash & Equiv.Liquid assets | $189M | $384M |
| Total DebtShort + long-term debt | $6M | $159M |
| Interest CoverageEBIT ÷ Interest expense | -118.34x | -81.62x |
BIOA leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RVMD leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RVMD five years ago would be worth $52,093 today (with dividends reinvested), compared to $10,082 for BIOA. Over the past 12 months, BIOA leads with a +367.3% total return vs RVMD's +303.5%. The 3-year compound annual growth rate (CAGR) favors RVMD at 83.5% vs BIOA's 0.3% — a key indicator of consistent wealth creation.
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… |
|---|---|---|
| YTD ReturnYear-to-date | +43.9% | +91.2% |
| 1-Year ReturnPast 12 months | +367.3% | +303.5% |
| 3-Year ReturnCumulative with dividends | +0.8% | +518.1% |
| 5-Year ReturnCumulative with dividends | +0.8% | +420.9% |
| 10-Year ReturnCumulative with dividends | +0.8% | +422.7% |
| CAGR (3Y)Annualised 3-year return | +0.3% | +83.5% |
RVMD leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
RVMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RVMD is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than BIOA's 1.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 97.0% from its 52-week high vs BIOA's 76.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.41x | 1.08x |
| 52-Week HighHighest price in past year | $24.00 | $155.70 |
| 52-Week LowLowest price in past year | $3.67 | $34.00 |
| % of 52W HighCurrent price vs 52-week peak | +76.9% | +97.0% |
| RSI (14)Momentum oscillator 0–100 | 43.6 | 64.2 |
| Avg Volume (50D)Average daily shares traded | 470K | 3.0M |
RVMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BIOA as "Buy" and RVMD as "Buy". Consensus price targets imply 143.8% upside for BIOA (target: $45) vs 2.5% for RVMD (target: $155).
| Metric | BIOABioAge Labs, Inc. | RVMDRevolution Medici… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $45.00 | $154.80 |
| # AnalystsCovering analysts | 3 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BIOA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RVMD leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallBioAge Labs, Inc. (BIOA)Leads 2 of 6 categories
Loading custom metrics...
BIOA vs RVMD: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is BIOA or RVMD a better buy right now?
Analysts rate BioAge Labs, Inc.
(BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — BIOA or RVMD?
Over the past 5 years, Revolution Medicines, Inc.
(RVMD) delivered a total return of +420. 9%, compared to +0. 8% for BioAge Labs, Inc. (BIOA). Over 10 years, the gap is even starker: RVMD returned +422. 7% versus BIOA's +0. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — BIOA or RVMD?
By beta (market sensitivity over 5 years), Revolution Medicines, Inc.
(RVMD) is the lower-risk stock at 1. 08β versus BioAge Labs, Inc. 's 1. 41β — meaning BIOA is approximately 30% more volatile than RVMD relative to the S&P 500. On balance sheet safety, BioAge Labs, Inc. (BIOA) carries a lower debt/equity ratio of 2% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — BIOA or RVMD?
On earnings-per-share growth, the picture is similar: BioAge Labs, Inc.
grew EPS 66. 2% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — BIOA or RVMD?
Revolution Medicines, Inc.
(RVMD) is the more profitable company, earning 0. 0% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0. 0% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — BIOA or RVMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is BIOA or RVMD better for a retirement portfolio?
For long-horizon retirement investors, Revolution Medicines, Inc.
(RVMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), +422. 7% 10Y return). Both have compounded well over 10 years (RVMD: +422. 7%, BIOA: +0. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between BIOA and RVMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.